Back

Business opportunities

Business opportunities

Areas of Excellence

  • Biology of blood components
  • Biology of stem cells
  • Human tissues
  • Maternal milk

Platforms and Partnership Opportunities

Over the years, Héma-Québec has developed and broadened a unique technological expertise. Areas of excellence and technology platforms implemented by Héma-Québec include:

  • Blood and blood components: optimization of collection, transport, preparation, quality control, storage, and distribution Hematopoietic stem cell culture; in vitro derivation of megakaryocytes and platelets; mesenchymal stem cell culture.
  • Analysis of cellular populations by multi-parametric flow cytometry and florescence microscopy, including confocal microscopy.
  • Human tissues: optimization of cleaning and bacterial decontamination processes; preparation of novel tissue compositions.
  • Maternal milk: optimization of preparation and decontamination processes; evaluation of residual bacterial load.

Héma-Québec believes that mobilizing the driving forces behind R&D in Québec contributes to the improvement of human health. Towards this goal, we encourage partnerships with academic and industrial stakeholders. These networking opportunities are aimed at fostering the growth of a dynamic and widespread ecosystem in the life sciences.

Héma-Québec offers its expertise and technological resources through various partnership models, such as:

  • Research collaboration agreements
  • Biological material transfer agreements
  • Service agreements
  • Research contracts

Our Patent Portfolio

Héma-Québec acknowledges that intellectual property developed by its staff constitutes a valuable asset to its mission and considers as its responsibility that this intellectual property be exploited in an optimal fashion for the benefit of all Quebecers.

Héma-Québec seeks to develop its patented technologies and other intellectual properties, preferably through licensing agreements. The patented technologies available for licensing are:

Description

This invention improves the in vitro expansion of hematopoietic stem cells, as well as the in vitro differentiation of these cells into blood platelet-producing cells. This technology is of clinical relevance, specially in the design of therapies involving hematopoietic stem cell transplantation

Countries/Territories

  • United States of America
  • Canada
  • Europe (granted European patent validated in France, Germany, and United Kingdom)

To learn more

Description

This invention claims a method allowing long-term in vitro expansion of memory B lymphocytes, as well as the production of polyclonal immunoglobulins. This technology could be a valuable asset in the development of novel methods of in vitro antibody production.

Countries/Territories

  • Canada
  • United States

To learn more 

Description

This invention claims a system of pouches filled with a eutectic gel and their use in the packaging of whole blood, allowing to rapidly cool and hold fresh blood at 20-24 °C during transport to a blood processing center. Rapid cooling and temperature hold of whole blood at 20-24 °C allows to improve standardization and quality of blood components.

Countries/Territories

  • Canada (granted)
  • United States (granted patents claiming methods for cooling whole blood, and for fabricating eutectic gel-containing pouches)
  • Europe (pending)

To learn more

Description

This invention claims a method for culturing hematopoietic stem cells that combines mild hyperthermia (culture temperature of 39 °C) and the use of a pyrimidoindole compound, in particular UM171. Hyperthermia and UM171 act synergistically to stimulate growth of hematopoietic stem cells. The synergistic effect is even more potent in a culture medium that favors the differentiation of hematopoietic stem cells towards the megakaryocytic lineage.

Countries/Territories

  • Canada (pending)
  • United States (pending)
  • Europe (pending)
  • Japan (pending)
  • South Korea (pending)
  • Australia (pending)
  • New Zealand (pending)
  • China (pending)
  • Israel (pending)
  • Singapore (pending)
  • Hong Kong (pending)

To learn more

Are you interested in one of our technologies?

Héma-Québec intends to generate value from its patented technologies and other intellectual properties, preferentially through the grant of licenses.

If you are interested by one of our technologies, or for any request for collaboration related to one of our areas of excellence, technological platforms or partnering opportunities, please contact:

Jean-François Leblanc, M.Sc.
Scientific Information Specialist
Vice-présidence aux affaires médicales et à l'innovation

Telephone: 418-780-4362,ext. 3281, or toll-free (Canada and the United States) 1-800-267-9711,ext. 3281
E-mail: Jean-Francois.Leblanc@hema-quebec.qc.ca

Top

Back